Диссертация (1174213), страница 47
Текст из файла (страница 47)
Roldan V. Renal impairment in a "real-life" cohort of anticoagulatedpatients with atrial fibrillation (implications for thromboembolism and bleeding)/Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M,Vicente V, Lip GY // Am J Cardiol.
– 2013. - №111. – Р.1159–1164.330. Rose AJ. Results of a Regional Effort to Improve WarfarinManagement /Rose AJ, Park A, Gillespie C, Van Deusen Lukas C, Ozonoff A,Petrakis BA, Reisman JI, Borzecki AM, Benedict AJ, Lukesh WN, Schmoke TJ,Jones EA, Morreale AP, Ourth HL, Schlosser JE, Mayo-Smith MF, Allen AL, WittDM, Helfrich CD,McCullough MB// Ann Pharmacother. – 2017. - №51(5). –Р.373-379. doi: 10.1177/1060028016681030.331. Rosendaal FR.
A method to determine the optimal intensity of oralanticoagulant therapy/Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E //Thromb Haemost. – 1993. - №69(3). – Р.236-9.332. Rudd KM. Comparison of two different models of anticoagulationmanagement services with usual medical care /Rudd KM, Dier JG //Pharmacotherapy. – 2010. -№ 30.
– Р.330–8.333. Ruddox V. Atrial fibrillation and the risk for myocardial infarction, allcause mortality and heart failure: A systematic review and meta-analysis /RuddoxV, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE // Eur J PrevCardiol. – 2017. - №24(14). – Р.1555-1566. doi: 10.1177/2047487317715769.334.
Ruff CT. Comparison of the efficacy and safety of new oralanticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis ofrandomised trials /Ruff CT, Giugliano RP, Braunwald E, Hoffman EB,Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A,Yamashita T, Antman EM // Lancet. – 2014. - №383.
– Р. 955–962.335. Russo C. Effect of obesity and overweight on left ventricular diastolicfunction: a community-based study in an elderly cohort /Russo C, Jin Z, Homma S,Rundek T, Elkind MS, Sacco RL, Di Tullio MR // J Am Coll Cardiol. – 2011. №57. – Р. 1368–1374.336. Sacco RL. Predictors of mortality and recurrence after hospitalizedcerebral infarction in an urban community: the Northern Manhattan Stroke Study/Sacco RL, Shi T, Zamanillo MC, Kargman DE // Neurol. - 1994. - Vol. 44.
- P.626–634.337. Saguner AM. Risk factors promoting hypertensive crises: evidencefrom a longitudinal study /Saguner AM, Dür S, Perrig M, Schiemann U, StuckAE, Bürgi U, Erne P, Schoenenberger AW. // Am J Hypertens. - 2010. - № 23(7).- Р.775-780.338. Sanchez PL. Structural heart disease: a new chapter in cardiovasculardisease /Sanchez PL, Fernandez-Aviles F // ESC Monographic issue: StructuralHeart Disease. Ed. Ruiz C.E. Eur Heart J. – 2010. - №12 (suppl. E). – Р.
e1.339. Sato H. Low-dose aspirin for prevention of stroke in low-risk patientswith atrial fibrillation: Japan Atrial Fibrillation Stroke Trial /Sato H, Ishikawa K,Kitabatake A, et al. // Stroke. – 2006. - № 37. – Р. 447–451.268340. Schneider MP. Prevention of atrial fibrillation by Renin-Angiotensinsystem inhibition a meta-analysis /Schneider MP, Hua TA, Bohm M,Wachtell K,Kjeldsen SE, Schmieder RE // J Am Coll Cardiol.
– 2010. - №55. – Р.2299–2307.341. Schoen T. Type 2 diabetes mellitus and risk of incident atrialfibrillation in women /Schoen T, Pradhan AD, Albert CM, Conen D // J Am CollCardiol. – 2012. - №60. – Р. 1421–1428.342. Schroeder K. How Can We Improve Adherence to Blood Pressure –Lowering Medication in Ambulatory Care? Systematic Review of RandomizedControlled Trials /Schroeder K, Ebrahim Sh// Arch Intern Med. – 2004. - № 164. –Р.
722–32.343. Schroeder K. Interventions for improving adherence to treatment inpatients with high blood pressure in ambulatory settings /Schroeder K, Fahey T,Ebrahim S // Cochrane Database Syst Rev. – 2004. - №2. – Р. CD004804.344. Semplicini A. Hypertension in acute ischemic stroke: a compensatorymechanism or an additional damaging factor? /Semplicini A, Maresca А, BoscoloG et al. // Arch Intern Med. - 2003.
- №6. - Р.163-211.345. Senoo K. Residual risk of stroke and death in anticoagulated patientsaccording to the type of atrial fibrillation: AMADEUS Trial /Senoo K, Lip GY,Lane DA, Buller HR, Kotecha D // Stroke. – 2015. - №46. – Р.2523–2528. doi:10.1161/STROKEAHA.115.009487.346. Sever PS. Prevention of cardiovascular events with anantihypertensive regimen of amlodipine adding perindopril as required versusatenolol adding bendroflumethiazide as required, in the Anglo-ScandinavianCardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlledtrial /Sever PS, Dahlof B, Poulter NR et al. for the ASCOT Investigators // Lancet.– 2005.
- № 366. – Р. 895–906.347. Shah M. Warfarin use and the risk for stroke and bleeding in patientswith atrial fibrillation undergoing dialysis /Shah M, AvgilTsadok M, JackeviciusCA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, GuoH, Pilote L // Circulation. – 2014. - №129. – Р.1196–1203.348. Shin HK.
Mild Included Hypertension Improves Blood Flow andoxygen metabolism in transient focal ischemia /Shin HK, Nishimura M, Jones PB// Stroke. - 2008. - №39. - Р. 1548-1555.349. Shore S. Site-level variation in and practices associated withdabigatran adherence /Shore S, Ho PM, Lambert-Kerzner A, Glorioso TJ, CareyEP, Cunningham F, Longo L, Jackevicius C, Rose A, Turakhia MP // JAMA. –2015. -№ 313. – Р.1443–50.350.
Siebert J. Hemodynamic findings in patients with brain stroke /SiebertJ, Gutknecht P, Molisz A, Trzeciak B, Nyka W // Arch Med Sci. – 2012. - №2. Р. 372-374.351. Simons LA. Medium- to long-term persistence with non-vitamin-K oralanticoagulants in patients with atrial fibrillation: Australian experience /SimonsLA, Ortiz M, Freedman B, Waterhouse BJ, Colquhoun D // Curr Med Res Opin. –2017. - №33(7). – Р. 1337-1341.
doi: 10.1080/03007995.2017.1321535.269352. Spah F. Potential beneficial effects of urapidil in primary andsecondary prevention of stroke /Spah F, Walsemann SO // Blood pressure. – 1995.- №4, Suppl. 3. – Р. 62-7.353. A randomized trial of intensive versus standard blood-pressurecontrol /SPRINT Research Group. // N. Engl.
J. Med. - 2015, - V. 373. - P. 2103–2116.354. Steg PG. RealiseAF investigators. Symptoms, functional status andquality of life in patients with controlled and uncontrolled atrial fibrillation: datafrom the RealiseAF cross-sectional international registry /Steg PG, Alam S,Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I,Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, Silva-Cardoso J, ZharinovO, Brette S, Neill JO// Heart.
– 2012. - № 98. – Р.195–201.355. Steinberg BA. Outcomes registry for better informed treatment ofatrial fibrillation II: rationale and design of the ORBIT-AF II registry /SteinbergBA, Blanco RG, Ollis D, et al. // Am Heart J. – 2014. - №168. – Р.160-167.356. Steinberg BA. International trends in clinical characteristics and oralanticoagulation treatment for patients with atrial fibrillation: Results from theGARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries /Steinberg BA, GaoH, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC,Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR, Ansell J, Mahaffey KW,Naccarelli G, Reiffel JA, Turpie A, Verheugt F, Piccini JP, Kakkar A,PetersonED, Fox KAA; GARFIELD-AF; ORBIT-AF Investigators// Am Heart J.
– 2017. №194. – Р.132-140.357. Steinberg BA. Higher risk of death and stroke in patients withpersistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial/Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ,et al; ROCKET-AF Steering Committee and Investigators //Eur Heart J. – 2015. № 36. – Р.288–296. doi: 10.1093/eurheartj/ehu359.358. Steinberg BA. Outcomes Registry for Better Informed Treatment ofAtrial Fibrillation (ORBIT-AF) Investigators and Patients. Early adoption ofdabigatran and its dosing in US patients with atrial fibrillation: results from theoutcomes registry for better informed treatment of atrial fibrillation /Steinberg BA,Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW,Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM // JAm Heart Assoc. – 2013.
- № 2(6). – Р.e000535. doi: 10.1161/JAHA.113.000535.359. Steinberg BA. Use and associated risks of concomitant aspirintherapy with oral anticoagulation in patients with atrial fibrillation: insights fromthe Outcomes Registry for Better Informed Treatment of Atrial Fibrillation(ORBIT-AF) Registry /Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD,Thomas L, Ezekowitz MD,Ansell J, Kowey P, Singer DE, Gersh B, MahaffeyKW, Hylek E, Go AS, Chang P,Peterson ED; ORBIT-AF Investigators andPatients // Circulation. – 2013. - №128(7). – Р.721-8. doi:10.1161/CIRCULATIONAHA.113.002927.270360.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
